Market assessment proposal for Animal Health Rapid Diagnostic

动物健康快速诊断市场评估建议

• 批准号: 567495-2021
• 负责人: Pardee, Keith
• 金额: $ 1.09万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=728656
• 关键词: Market; assessment; proposal; Animal; Health

The current market for animal disease diagnostics consists of two key categories of tests: molecular tests, such as the PCR test that must be completed in a fully equipped lab with trained personnel, and rapid tests such as lateral flow antigen tests, which can be performed by users with little training but are known to be unreliable. Recognizing the importance of this challenge, we employed synthetic biology methods to develop a molecular test, consisting of gene circuit-based sensors and cell free expression system (CFS), with a readout that can be interpreted using an off-the shelf blood glucose meter1. The widespread adoption of the glucose meter for diabetes management has resulted in a global network of device manufacturing and distribution, as well as broad acceptance by patients and clinicians for use by trained or naive users.We have recently demonstrated this technology for the detection of several diseases1, including paratyphoid A and B, which affect poultry2 and swine3, and COVID-19. We are adapting our technology to animal disease diagnostics, with the goal to put clinical-grade molecular tests into the hands of veterinarians and farm managers. This is a unique opportunity to provide lower-cost, more reliable diagnostic tests for important animal diseases in the companion animal, equine, or food animal health markets.We are applying to the I2I Market Assessment grant with the goal of reaching out to the industry and potential customers to identify customer needs and target markets. This will help inform and articulate our value proposition, which will allow us to optimize our market entry strategy for successful commercialization of our technology, as well as provide focus for our research and development efforts including selection of new disease targets.1. Amalfitano, E., Karlikow, M., Norouzi, M. et al.Nat Commun 12, 724 (2021).2. Shivaprasad, H. L. Rev Sci Tech. Aug;19(2):405-24 (2000).3. Patterson, S. K. et al. Anim Health Res Rev. Dec;17(2):159-168 (2016).

目前的动物疾病诊断市场由两类关键测试组成：分子测试，如必须在设备齐全、有训练有素的人员的实验室中完成的PCR测试，以及快速测试，如侧流抗原测试，用户只需很少的培训就可以进行，但已知不可靠。认识到这一挑战的重要性，我们利用合成生物学方法开发了一种分子测试，由基于基因电路的传感器和细胞自由表达系统(CFS)组成，读数可以使用现成的血糖仪1进行解释。血糖仪在糖尿病管理中的广泛应用已经形成了一个全球性的设备制造和分销网络，并被患者和临床医生广泛接受，供训练有素或新手使用。我们最近已经将这项技术用于几种疾病的检测1，包括影响鸡2和猪3的副伤寒A和B，以及新冠肺炎。我们正在将我们的技术应用于动物疾病诊断，目标是将临床级别的分子测试交到兽医和农场经理手中。这是一个独特的机会，可以为伴侣动物、马或食用动物健康市场中的重要动物疾病提供更低成本、更可靠的诊断测试。我们正在申请I2I市场评估基金，目标是接触行业和潜在客户，以确定客户需求和目标市场。这将有助于了解和阐明我们的价值主张，这将使我们能够优化我们的市场进入战略，使我们的技术成功商业化，并为我们的研究和开发努力提供重点，包括选择新的疾病目标1。2.Nat Commun 12,724(2021)2.首页--期刊主要分类--期刊细介绍--期刊细介绍.8月19日(2)：405-24(2000)。Patterson，S.K.等人。《动漫健康评论》12月；17(2)：159-168(2016)。